CCDRD

Executive Summary

CCDRD AG is a German contract research organization (CRO) specializing in the management and coordination of clinical trials from Phase I through Phase IV. Founded in 2018 and headquartered in Munich, the company supports a broad range of pharmaceutical products, including new chemical entities, biosimilars, biotechnology drugs, and generics. Its clinical infrastructure spans Europe and Asia, enabling efficient trial execution across diverse regulatory environments. CCDRD also provides regulatory strategy and support for interactions with major health authorities like the EMA and FDA, positioning itself as a comprehensive partner for drug development. Given its private status and early-stage operations, CCDRD has significant growth potential as it scales its clinical trial capabilities and expands its client base. The company is well-positioned to capitalize on the increasing outsourcing of clinical research by pharmaceutical and biotech firms. While specific financials are undisclosed, its focus on both innovative and generic drugs, along with its presence in key markets, suggests a steady revenue trajectory. Conviction is moderate, as the CRO space is competitive, but CCDRD’s value proposition is strengthened by its regulatory expertise and geographic footprint.

Upcoming Catalysts (preview)

• Q2 2026Major Contract Win with Top 20 Pharma Company60% success
• Q3 2026Expansion into U.S. Clinical Operations50% success
• Q2 2026Strategic Partnership with Asian Biotech Firm70% success